Zobrazeno 1 - 7
of 7
pro vyhledávání: '"John Lapek"'
Autor:
Xia Ding, Zhou Zhu, John Lapek, Elizabeth A. McMillan, Alexander Zhang, Chi-Yeh Chung, Sara Dubbury, Jennifer Lapira, Sarah Firdaus, Xiaolin Kang, Jingjin Gao, Jon Oyer, John Chionis, Robert A. Rollins, Lianjie Li, Sherry Niessen, Shubha Bagrodia, Lianglin Zhang, Todd VanArsdale
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-19 (2022)
Abstract The synthetic lethal association between BRCA deficiency and poly (ADP-ribose) polymerase (PARP) inhibition supports PARP inhibitor (PARPi) clinical efficacy in BRCA-mutated tumors. PARPis also demonstrate activity in non-BRCA mutated tumors
Externí odkaz:
https://doaj.org/article/b28d91d2e3b2470492e4d111d6c1fbcd
Autor:
Charlotte A Stoneham, Simon Langer, Paul D De Jesus, Jacob M Wozniak, John Lapek, Thomas Deerinck, Andrea Thor, Lars Pache, Sumit K Chanda, David J Gonzalez, Mark Ellisman, John Guatelli
Publikováno v:
PLoS Pathogens, Vol 17, Iss 11, p e1009409 (2021)
The HIV-1 accessory protein Vpu modulates membrane protein trafficking and degradation to provide evasion of immune surveillance. Targets of Vpu include CD4, HLAs, and BST-2. Several cellular pathways co-opted by Vpu have been identified, but the pic
Externí odkaz:
https://doaj.org/article/2522facbcf89469cb6071b09673a1333
Autor:
Neil J. Grimsey, Rachan Narala, Cara C. Rada, Sohum Mehta, Bryan S. Stephens, Irina Kufareva, John Lapek, David J. Gonzalez, Tracy M. Handel, Jin Zhang, JoAnn Trejo
Publikováno v:
Cell Reports, Vol 24, Iss 12, Pp 3312-3323.e5 (2018)
Summary: Ubiquitination is essential for protein degradation and signaling and pivotal to many physiological processes. Ubiquitination of a subset of G-protein-coupled receptors (GPCRs) by the E3 ligase NEDD4-2 is required for p38 activation, but how
Externí odkaz:
https://doaj.org/article/82640e8206af4d0dadef32fb621a95fe
Autor:
Mansi Arora, Justin Moser, Timothy E. Hoffman, Lotte P. Watts, Mingwei Min, Monica Musteanu, Yao Rong, Jordan Schneider, C Ryland Ill, Varuna Nangia, Manuel Sanclemente, John Lapek, Lisa Nguyen, Sherry Niessen, Stephen Dann, Todd van Arsdale, Mariano Barbacid, Nichol Miller, Sabrina L. Spencer
Publikováno v:
Cancer Research. 83:5992-5992
CDK2 is a core cell-cycle enzyme that phosphorylates a variety of substrates to drive progression through the cell cycle. CDK2 is hyperactivated in multiple cancers and is therefore an attractive therapeutic target. Here, application of a novel small
Autor:
Kephart Susan Elizabeth, Tran Khanh Tuan, Kevin Daniel Freeman-Cook, Sherry Niessen, James Solowiej, Buwen Huang, Qin Zhang, Douglas Carl Behenna, Inish O'Doherty, Sacha Ninkovic, Rose Ann Ferre, Andrea Hui, Nichol Miller, Jordan Carelli, Lisa Nguyen, Brion W. Murray, Robert Louis Hoffman, John Lapek, Rhys M. Jones, Meirong Xu, Stephen Dann, Sutton Scott Channing, Asako Nagata, Nanni Huser, Ravi Visswanathan, Zehnder Luke Raymond, Elaine E. Tseng, Britton Boras, You-Ai He, Michele McTigue, Wade Diehl, Cathy Zhang, Martha A. Ornelas
Publikováno v:
Journal of medicinal chemistry. 64(13)
Control of the cell cycle through selective pharmacological inhibition of CDK4/6 has proven beneficial in the treatment of breast cancer. Extending this level of control to additional cell cycle CDK isoforms represents an opportunity to expand to add
Autor:
Xinmeng Jasmine Mu, Meirong Xu, Shahram Salek-Ardakani, Cinthia Costa-Jones, Lisa Nguyen, James Solowiej, David Looper, Scott L. Weinrich, Robert Louis Hoffman, Sutton Scott Channing, Sacha Ninkovic, Kephart Susan Elizabeth, Sherry Niessen, John Chionis, Jadwiga Bienkowska, Kevin Daniel Freeman-Cook, Rose Ann Ferre, John Lapek, Cecilia Oderup, Jordan Carelli, Cathy Zhang, Nanni Huser, Elizabeth A. McMillan, Asako Nagata, Martha A. Ornelas, Brion W. Murray, Douglas Carl Behenna, Koleen Eisele, Todd VanArsdale, Zhou Zhu, Zhengyan Kan, Chaoting Liu, Nichol Miller, Zehnder Luke Raymond, Michael A. White, Ying Ding, Nathan V. Lee, Jonathan Almaden, Qin Zhang, Tran Khanh Tuan, Ping Wei, Stephen Dann, Britton Boras, Tim S. Wang, Ravi Visswanathan, You-Ai He, Michele McTigue, Elizabeth Wilson
Publikováno v:
Cancer Cell. 39:1404-1421.e11
Summary The CDK4/6 inhibitor, palbociclib (PAL), significantly improves progression-free survival in HR+/HER2− breast cancer when combined with anti-hormonals. We sought to discover PAL resistance mechanisms in preclinical models and through analys
Autor:
Nichol Miller, Sherry Niessen, Stephen Dann, Tim S. Wang, John Lapek, Chen Shen, Todd VanArsdale, Jon Almaden
Publikováno v:
Cancer Research. 81:1954-1954
CDK4/6 small molecule inhibitors represent a milestone in treating hormone receptor-positive breast cancer. PALOMA (Palbociclib: Ongoing Trials in the Management of Breast Cancer) studies have confirmed prolonged progression-free survival after CDK4/